Advanced

Follicular Lymphoma : Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

Matasar, Matthew J.; Luminari, Stefano; Barr, Paul M.; Barta, Stefan K.; Danilov, Alexey V.; Hill, Brian T.; Phillips, Tycel J.; Jerkeman, Mats LU ; Magagnoli, Massimo and Nastoupil, Loretta J., et al. (2019) In Oncologist
Abstract

Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often... (More)

Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs. Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Antineoplastic agents, Follicular lymphoma, Neoplasms, Non-Hodgkin lymphoma
in
Oncologist
publisher
AlphaMed Press
external identifiers
  • scopus:85070288652
ISSN
1083-7159
DOI
10.1634/theoncologist.2019-0138
language
English
LU publication?
no
id
f756132b-7a1f-402b-9113-299efbea216e
date added to LUP
2019-08-28 14:29:26
date last changed
2019-09-27 14:54:46
@article{f756132b-7a1f-402b-9113-299efbea216e,
  abstract     = {<p>Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs. Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.</p>},
  author       = {Matasar, Matthew J. and Luminari, Stefano and Barr, Paul M. and Barta, Stefan K. and Danilov, Alexey V. and Hill, Brian T. and Phillips, Tycel J. and Jerkeman, Mats and Magagnoli, Massimo and Nastoupil, Loretta J. and Persky, Daniel O. and Okosun, Jessica},
  issn         = {1083-7159},
  keyword      = {Antineoplastic agents,Follicular lymphoma,Neoplasms,Non-Hodgkin lymphoma},
  language     = {eng},
  publisher    = {AlphaMed Press},
  series       = {Oncologist},
  title        = {Follicular Lymphoma : Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs},
  url          = {http://dx.doi.org/10.1634/theoncologist.2019-0138},
  year         = {2019},
}